Welcome to the e-CCO Library!

P617: Switching from an intensified regimen of infliximab to a subcutaneous standard dose in adults with Inflammatory Bowel Disease: our experience in a tertiary hospital.
Year: 2022
Source: ECCO'22
Authors: Chivato Martín Falquina , I.(1);Saiz Chumillas , R.M.(1);Arias Garcia , L.(1);Vicente González , B.(2);Revilla Cuesta , N.(2);Alba Hernández , L.(1);Andrés Pascual , L.(1);Sicilia Aladrén , B.(1);
Created: Friday, 11 February 2022, 3:56 PM
P617: Trends in Pediatric Inflammatory Bowel Disease-attributable direct costs: A Canadian population-based analysis
Year: 2021
Source: ECCO'21 Virtual
Authors: El-Matary, W.(1);Nugent, Z.(2);Witt, J.(3);Bernstein, C.(4);
Created: Wednesday, 2 June 2021, 4:12 PM
P618 Post-operative Crohn’s disease patients undergoing colonoscopy require significantly more analgesia and sedation compared with a non-IBD population
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Rowan1, M. Janjua1, C. Foley1, J. Burke2, K. Boland1, A. O’Toole1

Created: Thursday, 30 January 2020, 10:12 AM
P618: Long-term real-world data of Ustekinumab in Ulcerative Colitis – the Stockholm Ustekinumab study – STOCUSTE
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Sabhan, H.(1)*;
Created: Friday, 14 July 2023, 11:05 AM
P618: Post-operative pain following laparoscopic right hemicolectomy for Crohn’s disease a comparative study
Year: 2018
Source: ECCO '18 Vienna
Authors:

K. McKevitt*, S. Galvin, J. Burke

Created: Thursday, 21 February 2019, 9:14 AM
P618: Pre-operative oral enteral nutritional optimisation for Crohn’s disease: A retrospective UK tertiary IBD centre cohort study
Year: 2022
Source: ECCO'22
Authors: Meade, S.(1);Patel, K.V.(2);Luber, R.P.(3);O’Hanlon, D.(4);Caracostea, A.(1);Pavlidis, P.(5);Honap, S.(1);Anandarajah, C.(1);Griffin, N.(6);Zeki, S.(1);Ray, S.(1);Mawdsley, J.(1);Samaan , M.A.(1);Anderson, S.H.(1);Darakhshan, A.(7);Adams, K.(7);Williams, A.(7);Sanderson, J.D.(1);Lomer, M.(4);Irving, P.M.(1);
Created: Friday, 11 February 2022, 3:56 PM
P618: Rapidity of onset of response to adalimumab in luminal Crohn's disease. Data from RAPIDA trial
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Marin-Jimenez I.*1, Casellas F.2, Esteve M.3, Castro-Laria L.4, García-Lόpez S.5, Ceballos D.6, Echarri A.7, Martín-Arranz M.D.8, Busquets D.9, Llaό J.10, Navarro-Llavat M.11, Huguet J.M.12, Argüelles-Arias F.4, Vicente R.5, Rodriguez-San Pedro L.13, Diaz G.14, Casado R.14, Barreiro-de Acosta M.15

Created: Wednesday, 20 February 2019, 10:36 AM
P618: Treatment outcomes of patients with Crohn’s disease and complex perianal fistula in five European countries: the PREFACE retrospective study
Year: 2021
Source: ECCO'21 Virtual
Authors: Ferrante, M.(1);Siproudhis, L.(2);Poggioli, G.(3);Reinshagen, M.(4);Milicevic, S.(5);Roset, M.(6);Bent-Ennakhi, N.(5);D‘Ambrosio, R.(5);Fernandez-Nistal, A.(7);Panes, J.(8);
Created: Wednesday, 2 June 2021, 4:12 PM
P618: Vedolizumab acute infusion reactions in inflammatory bowel disease patients: results of a multi-centre retrospective observational cohort study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

C. Venturin1, S. Nancey1, X. Roblin2, L. Peyrin-Biroulet3, N. Mathieu4, B. Flourié1, G. Boschetti*1

Created: Friday, 22 February 2019, 9:41 AM
P619 Efficacy of zinc acetate hydrate administration for zinc deficiency in patients with inflammatory bowel disease: a multi-centre retrospective study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

K. Sakurai1, T. Katsurada1, S. Otagiri1, K. Yamanashi1, K. Nagashima1, R. Onishi1, H. Nishimura2, T. Ito2, S. Furukawa2, A. Maemoto2, N. Sakamoto1

Created: Thursday, 30 January 2020, 10:12 AM
P619: Incidence of collagenous colitis in NHS Lothian: a population-based study
Year: 2021
Source: ECCO'21 Virtual
Authors: Grant, R.(1);Brindle, W.M.(1);Robertson, A.J.(2);Robertson, A.R.(1);Jones, G.R.(1);Kirkwood, K.J.(3);Fineron, P.W.(3);Arnott, I.D.R.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P619: Inflammatory bowel disease meets fertility: a physicians and patients survey
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Vieujean, S.(1)*;De Vos, M.(2);D'Amico, F.(3,4);Paridaens, K.(5);Daftary, G.(6);Peyrin-Biroulet, L.(7,8);Danese, S.(3);
Created: Friday, 14 July 2023, 11:05 AM
P619: Maintenance of efficacy following tofacitinib dose reduction in patients with ulcerative colitis in stable remission
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

D. T. Rubin1, S. Travis2, B. P. Abraham3, C. Su4, N. Lawendy4, H. Fan4, D. A. Woodworth4, A. J. Thorpe4, C. I. Nduaka4, D. Quirk4, W. Reinisch*5

Created: Friday, 22 February 2019, 9:41 AM
P619: Patterns of Anti-TNF Prescribing & Therapy Outcome in a Large Multicentre Cohort of Inflammatory Bowel Disease Patients
Year: 2022
Source: ECCO'22
Authors: Doherty, J.(1);Stack, R.(2);O Morain, N.(2);Coe, C.(2);Corcoran, R.(3);Ryan, B.(4);Doherty, G.(2);Mc Namara, D.(5);Kevans, D.(6);
Created: Friday, 11 February 2022, 3:56 PM
P619: Systematic review: Psychosocial factors associated with pain in inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

L. Sweeney1*, W. Czuber-Dochan1, R. Moss-Morris2, G. Chumbley3, L. Meade4, C. Norton1

Created: Thursday, 21 February 2019, 9:14 AM
P619: Tofacitinib for the treatment of resistant ulcerative colitis: the University of Chicago experience
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Weisshof R., Aharoni Golan M., Masching A., Rubin D.T.

Created: Wednesday, 20 February 2019, 10:36 AM
P620 Maintenance of clinical remission with SB5 biosimilar after switch from adalimumab originator: Real-life experience of a tertiary referral centre
Year: 2020
Source:

ECCO'20 Vienna

Authors:

G. Dragoni1,2, A. Pieraccini1, S. Bagnoli1, S. Caini3, G. Macrì1, F. Rogai1, S. Milani1,2, A. Galli1,2, M. Milla1

Created: Thursday, 30 January 2020, 10:12 AM
P620: Can ustekinumab trough and antidrug antibody levels post induction predict treatment failure?
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Mccrossan, M.(1)*;O'Moráin, N.(1,2);Kumar, L.(1,2);Rowan, C.(1);Sheridan, J.(1);Cullen, G.(1,2);Doherty, G.(1,2);Mulcahy, H.(1,2);
Created: Friday, 14 July 2023, 11:05 AM
P620: Differences in illness perceptions of Inflammatory Bowel Disease (IBD) between Healthcare Practitioners (HCPs) and patients in a UK tertiary IBD centre.
Year: 2022
Source: ECCO'22
Authors: Duff, A.(1);Dawson, P.(1);Pavilidis, P.(1);
Created: Friday, 11 February 2022, 3:56 PM
P620: Golimumab in ulcerative colitis: A multi-centre real-world experience
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Kumar1*, J. Slater1, J. Jones1, T. Troth2, G. Baker3, M. Love4, J. Nahal5, D. Rattehalli1

Created: Thursday, 21 February 2019, 9:14 AM